相关实验视频
Updated: Jun 18, 2025

07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.0K
甲胺对肠道微生物群和心血管健康的双重影响:全面分析
Turky Omar Asar1, Fahad A Al-Abbasi2, Ryan Adnan Sheikh2
1Department of Biology, College of Science and Arts at Alkamil, University of Jeddah, Jeddah, Saudi Arabia.
概括
甲胺改变了肠道微生物群的组成,影响了心血管健康,并可能加剧了多克索鲁比诱导的毒性. 这项研究揭示了甲胺,肠道细菌和心脏重塑之间的复杂相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 心脏病学 心脏病学
背景情况:
- 心血管疾病 (CVD) 构成了全球严重的健康负担.
- 肠道微生物群失调与心血管疾病的发展和进展有关.
- 多克索鲁比是一种已知的心脏毒性化疗剂.
研究的目的:
- 为了研究甲胺对多克索鲁比诱导的心血管毒性的影响.
- 在心脏毒性背景下探索甲福明对肠道微生物群组成的影响.
主要方法:
- 动物模型分为四个组:对照组,仅含甲胺,仅含多克索鲁比辛和多克索鲁比辛+甲胺.
- 从便样本进行肠道微生物分析 (α和β多样性).便样本.
- 对心脏生物标志物和炎症标志物的生物化学测试.
- 血液病理学检查心脏,肝脏和脏组织.
主要成果:
- doxorubicin 诱导了肠道微生物群多样性和组成的显著变化,某些 Firmicutes 属的流行率增加.
- 与多克索鲁比结合的梅特福林治疗显示降低了angiotensin II和renin水平.
- 观察到心脏损伤标志物 (CK-MB,Troponin),炎症标志物 (CRP,TNFɑ) 和纤维素原的水平升高.
- 组织病理学分析显示,在多克索鲁比+甲胺组中,心脏,肝脏和脏组织受损.
结论:
- 甲胺显著改变肠道微生物群,特别是影响菌和蛋白质细菌系.
- 在这种情况下,观察到的 ангиотензинII和宁的降低,加上炎症标志物和组织损伤的增加,表明metformin可能会对心血管产生不良影响.
- 需要进一步的研究来阐明甲胺,肠道微生物群和心血管健康之间的复杂相互作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Overview of Carbohydrate Metabolism
845
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
845
Factors Influencing Drug Absorption: Disease States and Pharmacology
481
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
481
What is Monogastric Digestion?
71.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
71.0K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180

